Sperm Donation — Cost, Top Hospitals & Success Rates | MyMedicPlus

Sperm donation is a process within reproductive medicine in which a male individual (the donor) voluntarily provides semen — the fluid containing sperm — to be used by another person or couple (the recipient) to achieve pregnancy through medically assisted reproduction. It is one of the oldest and most widely used forms of third-party reproduction, with documented clinical use dating to the late 19th century and widespread practice since the 1970s following the development of reliable sperm cryopreservation (freezing) techniques.

The donated sperm, after rigorous medical and genetic screening, is used in one of three principal assisted reproductive techniques:

• Intrauterine insemination (IUI): Processed (washed and concentrated) sperm is introduced directly into the uterine cavity through a fine catheter at the time of ovulation — the simplest and least invasive approach
• In vitro fertilisation (IVF): Eggs retrieved from the recipient or an egg donor are fertilised by donor sperm in the laboratory; one or more resulting embryos are transferred to the uterus
• Intracytoplasmic sperm injection (ICSI): A single donor sperm is injected directly into an individual egg — used when standard IVF fertilisation rates are suboptimal

Donated sperm is typically cryopreserved in liquid nitrogen at −196°C and quarantined for a mandatory period (commonly 3–6 months) pending repeat infectious disease testing of the donor before release for clinical use. Fresh donor sperm is rarely used in modern practice due to infectious disease transmission risk.

Sperm donation is regulated by national legislation in most countries, covering anonymity versus open-identity donation, maximum number of families per donor, mandatory screening, and compensation. Legal parentage of the resulting child is assigned to the recipient (and their partner if applicable), not the donor, in almost all jurisdictions with specific legislation in place.

Donor sperm is used by a range of individuals and couples whose circumstances prevent conception using the male partner's own sperm, or where no male partner is present:

• Azoospermia: Complete absence of sperm in the ejaculate, affecting approximately 1% of all men. In non-obstructive azoospermia (failure of sperm production due to testicular failure, genetic causes such as Klinefelter syndrome, or prior chemotherapy/radiotherapy), surgical sperm retrieval may be unsuccessful, making donor sperm the only path to biological parenthood for the recipient.
• Severe oligospermia: Severely reduced sperm count (<1–5 million per mL) with poor motility or morphology, where the probability of achieving pregnancy with the male partner's own sperm — even with ICSI — is unacceptably low after failed treatment cycles.
• Genetic disease in the male partner: Men carrying autosomal dominant conditions (e.g., Huntington's disease, myotonic dystrophy) or X-linked disorders with a high risk of transmission to offspring may opt for donor sperm to avoid passing the condition to their children, particularly when pre-implantation genetic testing (PGT) is not feasible or acceptable.
• Recurrent fertilisation failure: Repeated failure of fertilisation in IVF/ICSI cycles despite apparently normal sperm parameters, suggesting a sperm factor affecting fertilisation that cannot be corrected.
• Same-sex female couples: Lesbian couples and civil partners routinely use donor sperm as an integral component of their path to biological parenthood via IUI, IVF, or reciprocal IVF (where one partner provides the egg and the other carries the pregnancy).
• Single women by choice: Increasing numbers of single women choose donor sperm to conceive without a male partner, supported by evolving social norms and legislation in many countries.
• Infectious disease risk: HIV-positive male partners with undetectable viral load can in many cases use their own sperm safely, but donor sperm may be preferred in specific high-risk scenarios after counselling.

Rigorous donor selection is the cornerstone of a safe and ethical sperm donation programme. Criteria are broadly consistent with guidance from the World Health Organization (WHO), the European Society of Human Reproduction and Embryology (ESHRE), and national bodies such as the HFEA (UK) and FDA (US):

Basic Eligibility Criteria for Donors

• Age: typically 18–40 years (many programmes prefer donors under 35 years given an association between advanced paternal age and de novo genetic mutations)
• Good general physical and mental health
• Semen parameters meeting minimum thresholds: total motile sperm count after freeze-thaw of at least 5 million (many centres require 10–20 million), progressive motility ≥32%, normal morphology (WHO 2010 criteria) ≥4%
• Non-smoker; limited or no alcohol and recreational drug use
• No history of inherited genetic conditions in the donor or immediate family members

Mandatory Screening Tests

• Infectious disease: HIV-1 and HIV-2 antibody and antigen, hepatitis B surface antigen, hepatitis B core antibody, hepatitis C antibody, syphilis (VDRL/TPHA), CMV IgG and IgM, HTLV-I/II, Zika virus (in relevant regions), gonorrhoea and chlamydia (urethral/urine PCR)
• Genetic karyotype: Conventional chromosomal karyotype (46,XY); Y-chromosome microdeletion screen; cystic fibrosis mutation panel (mandatory in most jurisdictions)
• Extended genetic carrier screening: Many programmes now offer expanded carrier screening panels testing for 200–400+ autosomal recessive conditions (spinal muscular atrophy, fragile X, haemoglobinopathies, lysosomal storage disorders) to enable matching with recipients and avoid offspring risk
• Medical and psychological history: Detailed personal and three-generation family history reviewed by a clinical geneticist; psychological assessment to confirm voluntary, informed consent and absence of coercive circumstance

Quarantine Period

Cryopreserved sperm samples must be quarantined for a minimum of 90 days (6 months in some jurisdictions) after donation, with repeat infectious disease testing of the donor before release. This window period approach eliminates the risk of transmitting infections that were in the seronegative window phase at initial testing.

Donor sperm can be used in several assisted reproductive techniques, selected based on the recipient's diagnosis, age, ovarian reserve, and clinical history:

Intrauterine Insemination (IUI) with Donor Sperm (DI — Donor Insemination)

The simplest and least expensive technique. A thawed and washed sperm sample is introduced directly into the uterine cavity using a fine catheter, timed to coincide with natural or stimulated ovulation. IUI is suitable for women under 35 years with a normal uterus, at least one patent fallopian tube, and adequate ovarian reserve. Mild ovarian stimulation (clomiphene citrate or low-dose gonadotrophins) may be used to improve the chance of ovulation and increase the probability of conception per cycle. Success rates per cycle range from 10–20%, and cumulative pregnancy rates over 3–6 cycles approach 50–70% in women under 35 with no additional infertility factors.

In Vitro Fertilisation (IVF) with Donor Sperm

Eggs are retrieved from the recipient under ultrasound guidance following controlled ovarian stimulation, mixed with donor sperm in the laboratory, and fertilised. Resulting embryos are cultured to day 3 (cleavage stage) or day 5 (blastocyst) and one or two selected embryos are transferred to the uterus. IVF with donor sperm is indicated when the recipient has blocked tubes, diminished ovarian reserve requiring maximal stimulation, or when IUI has failed. Clinical pregnancy rates per embryo transfer cycle are 40–60% in women under 35 using own eggs.

IVF with Donor Sperm and Donor Eggs (Double Donation)

When both sperm and eggs from third-party donors are used, this is referred to as double donation or embryo donation from unrelated donors. Used for recipients with both severe male factor infertility in a partner and poor or absent egg production in the recipient herself (e.g., premature ovarian insufficiency). Pregnancy rates per transfer are high (60–70%) given the youth and health of both donors.

Reciprocal IVF (Same-Sex Female Couples)

Eggs are retrieved from one partner (the genetic mother), fertilised with donor sperm, and the resulting embryo is transferred to the other partner (the gestational mother). This allows both women in a couple to participate biologically in the pregnancy. The procedure is legally available and widely practised in many countries with permissive legislation.

Sperm Matching and Open-Identity Donation

Most sperm banks provide phenotypic matching (blood group, eye colour, hair colour, height, ethnicity) and, increasingly, extended genetic compatibility matching. Many countries — including the UK, the Netherlands, Sweden, Austria, Norway, and New Zealand — mandate open-identity (non-anonymous) donation, meaning donor-conceived children may apply for identifying information about their donor upon reaching adulthood (typically age 18). Prospective recipients should understand the legal framework in their jurisdiction and consider counselling on the implications of donor conception for their future child.

Sperm donation enables pregnancy and parenthood in situations that would otherwise be biologically impossible:

• Enables parenthood for couples with severe male infertility: For men with non-obstructive azoospermia where surgical sperm retrieval has failed, donor sperm is the only means of achieving biological pregnancy for the female partner without adoption.
• High cumulative success rates: Cumulative live birth rates over 3–6 IUI cycles with donor sperm approach 50–70% in women under 35 years of age with no additional female infertility factors. IVF with donor sperm in the same demographic achieves live birth rates of 40–55% per transfer cycle.
• Reduced genetic risk transmission: Couples at risk of transmitting serious inherited conditions to offspring can use screened donor sperm to eliminate or substantially reduce this risk without the ethical and logistical challenges of pre-implantation genetic testing of their own embryos.
• Access to safe, screened material: Modern sperm banks subject all donated samples to rigorous infectious disease testing, genetic screening, and mandatory quarantine, making the risk of infectious disease or genetic disorder transmission from donated sperm extremely low.
• Empowers diverse family structures: Single women and same-sex female couples are able to achieve biological parenthood using donor sperm, providing an important option that respects reproductive autonomy and diverse family building aspirations.
• Flexible storage: Cryopreserved donor sperm can be stored for many years without loss of viability (demonstrated successful pregnancies after sperm stored for 21+ years). This allows recipients to use sperm from the same donor for additional siblings across multiple treatment cycles.

Sperm donation is a safe, well-regulated procedure, but recipients and donors should be aware of the following medical, legal, and psychosocial considerations:

Medical Risks

• Infectious disease transmission: Extremely rare with quarantine protocols and serial testing, but theoretically possible for pathogens with very long window periods. Recipients with specific concerns should discuss additional testing options with their clinic.
• Genetic disease transmission: Comprehensive carrier screening substantially reduces this risk. Recipients may choose to undergo their own carrier genetic testing and request a donor with a compatible (non-carrier) status for conditions identified. Even so, unknown de novo mutations cannot be screened in advance.
• Multiple pregnancy: Ovarian stimulation used in IUI cycles increases the risk of multiple follicle development and twin or higher-order multiple pregnancy. Careful monitoring and dose adjustment by the fertility specialist minimises this risk.
• Ovarian hyperstimulation syndrome (OHSS): In IVF cycles involving ovarian stimulation, OHSS is a risk — ranging from mild bloating to, rarely, severe fluid shifts requiring hospitalisation. Modern stimulation protocols and trigger agent selection have substantially reduced severe OHSS incidence.
• Failure to conceive: As with all assisted reproduction, there is no guarantee of pregnancy. Factors influencing success include recipient age, ovarian reserve, uterine health, and the quality of the frozen-thawed sperm sample.

Psychosocial and Ethical Considerations

• Donor-conceived child's identity: Evidence supports early, age-appropriate disclosure of donor conception to children. Donor-conceived individuals have a right to information about their genetic origins. The move toward open-identity donation internationally reflects this understanding.
• Donor limits and sibling groups: Most regulatory bodies limit the number of families per donor (10–25 in most European countries; up to 25 in the UK; variable in the US) to reduce the risk of inadvertent consanguinity among donor-conceived half-siblings.
• Recipient counselling: Independent counselling by a fertility counsellor — separate from the treating clinic — is mandatory or strongly recommended in most jurisdictions, covering implications for the recipient, their partner, and the future child.

Legal Considerations

Laws governing donor anonymity, parentage, compensation, and family limits vary significantly by country. Recipients seeking treatment abroad should seek legal advice regarding how donor conception is legally recognised in their country of residence, particularly regarding parental rights of any resulting children.

The sperm donation process follows a structured pathway for both donors and recipients:

Donor Process

1. Initial assessment: Application, semen analysis, and preliminary health history review (1–2 weeks)
2. Full medical and genetic screening: Blood tests, karyotype, extended carrier screen, physical examination, psychological assessment (4–8 weeks)
3. Sample donation sessions: Donors provide multiple ejaculates (typically 10–25 samples) at the bank's facility. Each sample is processed, tested, frozen, and labelled.
4. Quarantine period: Samples stored under quarantine for 90–180 days.
5. Repeat donor testing: Repeat infectious disease tests confirm donor remains negative; samples released for clinical use.
6. Ongoing reporting: Donors are asked to notify the sperm bank of any new genetic diagnoses or infectious disease events.

Recipient Process

1. Referral and initial consultation: Reproductive history, pelvic assessment (ultrasound), ovarian reserve testing (AMH, antral follicle count), blood tests
2. Counselling: Mandatory or recommended implications counselling with an accredited fertility counsellor
3. Donor selection: Recipient selects an appropriate donor from the bank's catalogue based on phenotypic profile and genetic compatibility
4. Treatment cycle: Natural, medicated, or stimulated IUI or IVF cycle as appropriate; sperm thawed on the day of insemination or egg collection
5. Pregnancy test: Serum hCG at 14 days post-insemination or embryo transfer
6. Obstetric care: If pregnancy is confirmed, care transitions to obstetric services. Donor-conceived pregnancy carries no specific additional obstetric risk.

After Treatment

Recipients are encouraged to inform their fertility clinic of any pregnancy outcome — positive or negative — to support accurate outcome data collection. Confirmed live births should be notified to the sperm bank to update the donor's family count. Psychological support through the fertility clinic or independent counselling is available for those who experience repeated failures or who are processing the complex emotions that donor conception can evoke.

The cost of treatment using donor sperm varies by type of assisted reproductive treatment used, the country, the clinic, and whether purchased sperm is from a domestic or international bank:

Estimated Costs by Country

• United States: USD 300–1,000 per vial of donor sperm from a licensed bank; USD 800–2,500 per IUI cycle (clinic fees); USD 12,000–25,000 per IVF cycle with donor sperm
• United Kingdom: GBP 500–1,500 per IUI cycle (NHS funding for IUI with donor sperm is increasingly limited; private cost); GBP 4,000–8,000 per IVF cycle with donor sperm
• Spain: EUR 1,000–2,000 per IUI cycle; EUR 5,000–9,000 per IVF cycle — one of Europe's most popular fertility tourism destinations due to liberal legislation and high-quality clinics
• India: USD 400–900 per IUI cycle (clinic fees + sperm); USD 2,500–5,000 per IVF cycle with donor sperm at accredited clinics
• Czech Republic: EUR 1,000–2,500 per IUI cycle; EUR 3,000–6,000 per IVF cycle
• Thailand: USD 1,500–3,500 per IUI cycle; USD 5,000–10,000 per IVF cycle

Factors Affecting Cost

• Type of treatment: IUI is significantly less expensive than IVF; the cost difference becomes relevant when considering the lower per-cycle success rate of IUI requiring more cycles
• Donor sperm cost: Vial cost varies by sperm bank, donor preparation, shipping from international banks, and quantity ordered
• Ovarian stimulation medications: Gonadotrophin injections for IVF stimulation add USD 1,000–4,000 per cycle in the US (lower elsewhere)
• Embryo freezing and storage: Additional embryos from IVF cycles may be cryopreserved at USD 500–1,500 per year
• Genetic testing of embryos: Pre-implantation genetic testing (PGT-A) for chromosomal normality adds USD 2,000–5,000 per cycle but may improve success rates and reduce miscarriage in older recipients

Spain, the Czech Republic, and India are leading medical tourism destinations for donor sperm IVF, offering internationally trained reproductive medicine specialists, English-speaking staff, and rigorous donor screening at substantially lower cost than in the United States or United Kingdom.

Before deciding on donor sperm, couples with male factor infertility should explore whether other approaches might enable conception with the male partner's own genetic material:

Surgical Sperm Retrieval

In men with obstructive azoospermia (sperm production is normal but the ductal system is blocked due to vasectomy, congenital absence of the vas deferens, or epididymal obstruction), sperm can be retrieved surgically from the epididymis (PESA — percutaneous epididymal sperm aspiration, or MESA — microsurgical epididymal sperm aspiration) or from the testicle (TESA/TESE/microTESE). Retrieved sperm is used for ICSI. Success rates with obstructive azoospermia are excellent (ICSI live birth rates equivalent to ejaculatory sperm in many studies).

Micro-TESE for Non-Obstructive Azoospermia

Microsurgical testicular sperm extraction (micro-TESE) uses an operating microscope to identify and harvest the few sperm-producing tubules present in testes with otherwise absent sperm production. Sperm retrieval rates of 30–60% are reported in experienced centres, allowing ICSI attempts with the partner's own genetic material.

Medical Treatment of Male Infertility

Hormonal causes of impaired sperm production — including hypogonadotropic hypogonadism (low FSH and LH causing poor testicular stimulation) — are treatable with gonadotrophin injections (hCG plus FSH) that restore testicular testosterone production and spermatogenesis. Varicocele (dilated testicular veins) repair may improve sperm parameters in selected cases.

Embryo Adoption / Embryo Donation

Couples with both male factor and female factor infertility, or who wish to avoid the genetic contribution of both partners, may adopt surplus embryos donated by other IVF couples. This offers a potentially lower-cost path to pregnancy than donor sperm IVF with the recipient's own eggs, though availability of donated embryos varies widely by country and programme.

Adoption and Foster Care

For individuals and couples who are unable or unwilling to pursue assisted reproduction, domestic or international adoption and foster care offer pathways to parenthood outside of biological reproduction. Eligibility criteria and wait times vary significantly by jurisdiction and individual circumstances.